T2 Biosystems(TTOO.US)

Company Encyclopedia
View More
name
T2 Biosystems
TTOO.US
T2 Biosystems, Inc. engages in the development and commercialization of medical diagnostic products for critical unmet needs in the healthcare. Its products include T2Dx instrument, T2Candida panel, and T2Bacteria panel. The company was incorporated in 2006 and is based in Lexington, Massachusetts.
1.906 T
TTOO.USMarket value -Rank by Market Cap -/-

Financial Score

31/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking344/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE277.61%A
    • Profit Margin-559.52%E
    • Gross Margin-239.85%E
  • Growth ScoreD
    • Revenue YoY-30.19%E
    • Net Profit YoY13.81%C
    • Total Assets YoY-58.22%E
    • Net Assets YoY39.12%A
  • Cash ScoreD
    • Cash Flow Margin-17.87%D
    • OCF YoY-30.19%E
  • Operating ScoreD
    • Turnover0.25D
  • Debt ScoreE
    • Gearing Ratio164.76%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    U.S. stock market close | Three major indices rise for five consecutive days, S&P and Dow hit new highs before the holiday!

    U.S. stock market closed with all three major indices rising, achieving five consecutive days of gains. Both the Dow Jones and S&P 500 set new historical highs, while the Nasdaq remained strong. Macroeconomic data showed moderate employment figures and easing inflation pressures, with investors focusing on the Federal Reserve's next policy moves. Popular stocks such as T2 Biosystems, Yellow Corporation, and Sorrento Therapeutics surged significantly, with funds actively flowing into high-elasticity themes. The top ten trading volumes in the market showed significant divergence, with leading stocks experiencing increased volatility

    Market Heartbeat·
    US
    TTOO
    -13.04%
    Market Heartbeat·
    US
    TTOO
    -13.04%

    The 9 top biotech startups from Disrupt Startup Battlefield

    TechCrunch's Startup Battlefield featured top biotech startups, including CasNx, Chipiron, Exactics, Lumos Strategies OÜ, Miraqules, Nephrogen, PraxisPro, Reme-D, and Surgicure Technologies. These startups showcased innovations in gene-editing, MRI diagnostics, rapid tests, electromagnetic therapy, nanotechnology, gene therapy, AI training, affordable diagnostics, and medical devices. The competition highlights the potential impact of these technologies in healthcare.

    TechCrunch·
    TechCrunch·

    T2 Inc. announced that it has received funding from SBI Investment Co., Ltd., Tokyu Fudosan Holdings Corporation

    T2 Inc announced that it has received a round of funding on October 6, 2025. The transaction included participation from new investor Tokyu Fudosan Holdings Corporation CVC fund, TSVF2 Fund, fund managed by SBI Investment Co., Ltd. The company issued convertible preferred stock in this transaction.

    marketscreener·
    US
    TTOO
    -13.04%
    marketscreener·
    US
    TTOO
    -13.04%

    T2 Biosystems Reduces Workforce Amid Nasdaq Delisting Notice

    T2 Biosystems (TTOO) announced a significant workforce reduction affecting nearly all employees, incurring one-time charges of $1.0 million for termination costs. Key executives were terminated but reappointed as consultants. The company also canceled a Special Meeting of Stockholders and abandoned a proposed reverse stock split following a Nasdaq delisting notice. T2 Biosystems focuses on innovative medical diagnostics, particularly in rapid pathogen detection. Year-to-date, the stock has declined by 83.75%, with a current market cap of $1.83 million.

    Tip Ranks·
    US
    TTOO
    -13.04%
    Tip Ranks·
    US
    TTOO
    -13.04%

    T2 Biosystems Gets Nasdaq Delisting Notice; Shares Down

    T2 Biosystems said Tuesday the Nasdaq Hearings Panel has determined to delist its shares, with trading of the stock to be suspended from Feb. 12. The company said it does not plan to pursue any further appeal of the ruling after it failed to meet the requirements for bid price and the market value of listed securities. T2 said its shares are expected to begin trading on the OTC Markets system Wednesday. Shares of T2 Biosystems were down about 20% in recent trading.

    Trading View·
    US
    TTOO
    -13.04%
    Trading View·
    US
    TTOO
    -13.04%
    © 2025 Longbridge｜Disclaimer